12:00 AM
 | 
Mar 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Feraheme ferumoxytol regulatory update

AMAG said FDA accepted for review an sNDA to expand the indication for Feraheme ferumoxytol to include the treatment of all adult patients with iron deficiency anemia who have failed or could not tolerate oral iron treatment. The PDUFA date is...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >